Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 210

1.

Deciphering the chronology of copy number alterations in Multiple Myeloma.

Aktas Samur A, Minvielle S, Shammas M, Fulciniti M, Magrangeas F, Richardson PG, Moreau P, Attal M, Anderson KC, Parmigiani G, Avet-Loiseau H, Munshi NC, Samur MK.

Blood Cancer J. 2019 Mar 26;9(4):39. doi: 10.1038/s41408-019-0199-3.

2.

The Admission Experience Survey Italian Version (I-AES): A factor analytic study on a sample of 156 acute psychiatric in-patients.

Mandarelli G, Parmigiani G, Trobia F, Tessari G, Roma P, Biondi M, Ferracuti S.

Int J Law Psychiatry. 2019 Jan - Feb;62:111-116. doi: 10.1016/j.ijlp.2018.12.006. Epub 2018 Dec 19.

PMID:
30616845
3.

Transcriptome Deconvolution of Heterogeneous Tumor Samples with Immune Infiltration.

Wang Z, Cao S, Morris JS, Ahn J, Liu R, Tyekucheva S, Gao F, Li B, Lu W, Tang X, Wistuba II, Bowden M, Mucci L, Loda M, Parmigiani G, Holmes CC, Wang W.

iScience. 2018 Nov 30;9:451-460. doi: 10.1016/j.isci.2018.10.028. Epub 2018 Nov 2.

4.

Synergy of cytological methods in the pathological staging of breast cancer: Axillary fine-needle aspiration and intraoperative scrape cytology of the sentinel lymph node.

Bruzzone M, Saro F, Bruno S, Celiento T, Mazzarella G, Lanata S, Aquilano MC, Parmigiani G, Pollone M, Gandolfo F, Costigliolo G, Sironi M.

Diagn Cytopathol. 2018 Nov;46(11):919-926. doi: 10.1002/dc.23995. Epub 2018 Oct 24.

PMID:
30353679
5.

A Prospective Study of the Association between Physical Activity and Risk of Prostate Cancer Defined by Clinical Features and TMPRSS2:ERG.

Pernar CH, Ebot EM, Pettersson A, Graff RE, Giunchi F, Ahearn TU, Gonzalez-Feliciano AG, Markt SC, Wilson KM, Stopsack KH, Gazeeva E, Lis RT, Parmigiani G, Rimm EB, Finn SP, Giovannucci EL, Fiorentino M, Mucci LA.

Eur Urol. 2019 Jul;76(1):33-40. doi: 10.1016/j.eururo.2018.09.041. Epub 2018 Oct 6.

PMID:
30301696
6.

Multi-study factor analysis.

De Vito R, Bellio R, Trippa L, Parmigiani G.

Biometrics. 2019 Mar;75(1):337-346. doi: 10.1111/biom.12974. Epub 2019 Mar 8.

PMID:
30289163
7.

Continuity of transcriptomes among colorectal cancer subtypes based on meta-analysis.

Ma S, Ogino S, Parsana P, Nishihara R, Qian Z, Shen J, Mima K, Masugi Y, Cao Y, Nowak JA, Shima K, Hoshida Y, Giovannucci EL, Gala MK, Chan AT, Fuchs CS, Parmigiani G, Huttenhower C, Waldron L.

Genome Biol. 2018 Sep 25;19(1):142. doi: 10.1186/s13059-018-1511-4.

8.

The impact of different sources of heterogeneity on loss of accuracy from genomic prediction models.

Zhang Y, Bernau C, Parmigiani G, Waldron L.

Biostatistics. 2018 Sep 6. doi: 10.1093/biostatistics/kxy044. [Epub ahead of print]

PMID:
30202918
9.

Nonparametric Adjustment for Measurement Error in Time-to-Event Data: Application to Risk Prediction Models.

Braun D, Gorfine M, Katki HA, Ziogas A, Parmigiani G.

J Am Stat Assoc. 2018;113(521):14-25. doi: 10.1080/01621459.2017.1311261. Epub 2017 Sep 14.

10.

Consensus on Molecular Subtypes of High-Grade Serous Ovarian Carcinoma.

Chen GM, Kannan L, Geistlinger L, Kofia V, Safikhani Z, Gendoo DMA, Parmigiani G, Birrer M, Haibe-Kains B, Waldron L.

Clin Cancer Res. 2018 Oct 15;24(20):5037-5047. doi: 10.1158/1078-0432.CCR-18-0784. Epub 2018 Jul 3.

PMID:
30084834
11.

Family History of Breast or Prostate Cancer and Prostate Cancer Risk.

Barber L, Gerke T, Markt SC, Peisch SF, Wilson KM, Ahearn T, Giovannucci E, Parmigiani G, Mucci LA.

Clin Cancer Res. 2018 Dec 1;24(23):5910-5917. doi: 10.1158/1078-0432.CCR-18-0370. Epub 2018 Aug 6.

PMID:
30082473
12.

Shared and Study-specific Dietary Patterns and Head and Neck Cancer Risk in an International Consortium.

De Vito R, Lee YCA, Parpinel M, Serraino D, Olshan AF, Zevallos JP, Levi F, Zhang ZF, Morgenstern H, Garavello W, Kelsey K, McClean M, Schantz S, Yu GP, Boffetta P, Chuang SC, Hashibe M, La Vecchia C, Parmigiani G, Edefonti V.

Epidemiology. 2019 Jan;30(1):93-102. doi: 10.1097/EDE.0000000000000902.

13.

Efficient computation of the joint probability of multiple inherited risk alleles from pedigree data.

Madsen T, Braun D, Peng G, Parmigiani G, Trippa L.

Genet Epidemiol. 2018 Sep;42(6):528-538. doi: 10.1002/gepi.22130. Epub 2018 Jun 25.

PMID:
29943416
14.

Precision Prevention and Early Detection of Cancer: Fundamental Principles.

Rebbeck TR, Burns-White K, Chan AT, Emmons K, Freedman M, Hunter DJ, Kraft P, Laden F, Mucci L, Parmigiani G, Schrag D, Syngal S, Tamimi RM, Viswanath K, Yurgelun MB, Garber JE.

Cancer Discov. 2018 Jul;8(7):803-811. doi: 10.1158/2159-8290.CD-17-1415. Epub 2018 Jun 15.

PMID:
29907587
15.

Long intergenic non-coding RNAs have an independent impact on survival in multiple myeloma.

Samur MK, Minvielle S, Gulla A, Fulciniti M, Cleynen A, Aktas Samur A, Szalat R, Shammas M, Magrangeas F, Tai YT, Auclair D, Keats J, Richardson P, Attal M, Moreau P, Anderson KC, Parmigiani G, Avet-Loiseau H, Munshi NC.

Leukemia. 2018 Dec;32(12):2626-2635. doi: 10.1038/s41375-018-0116-y. Epub 2018 Mar 29.

16.

Training replicable predictors in multiple studies.

Patil P, Parmigiani G.

Proc Natl Acad Sci U S A. 2018 Mar 13;115(11):2578-2583. doi: 10.1073/pnas.1708283115. Epub 2018 Mar 12.

17.

The clinical trials landscape for glioblastoma: is it adequate to develop new treatments?

Vanderbeek AM, Rahman R, Fell G, Ventz S, Chen T, Redd R, Parmigiani G, Cloughesy TF, Wen PY, Trippa L, Alexander BM.

Neuro Oncol. 2018 Jul 5;20(8):1034-1043. doi: 10.1093/neuonc/noy027.

PMID:
29518210
18.

A Clinical Decision Support Tool to Predict Cancer Risk for Commonly Tested Cancer-Related Germline Mutations.

Braun D, Yang J, Griffin M, Parmigiani G, Hughes KS.

J Genet Couns. 2018 Sep;27(5):1187-1199. doi: 10.1007/s10897-018-0238-4. Epub 2018 Mar 2.

PMID:
29500626
19.

Expressed fusion gene landscape and its impact in multiple myeloma.

Cleynen A, Szalat R, Kemal Samur M, Robiou du Pont S, Buisson L, Boyle E, Chretien ML, Anderson K, Minvielle S, Moreau P, Attal M, Parmigiani G, Corre J, Munshi N, Avet-Loiseau H.

Nat Commun. 2017 Dec 1;8(1):1893. doi: 10.1038/s41467-017-00638-w.

20.

Adding experimental arms to platform clinical trials: randomization procedures and interim analyses.

Ventz S, Cellamare M, Parmigiani G, Trippa L.

Biostatistics. 2018 Apr 1;19(2):199-215. doi: 10.1093/biostatistics/kxx030.

21.

Integrative factor analysis - An unsupervised method for quantifying cross-study consistency of gene expression data.

Wang XV, Parmigiani G.

Genomics. 2018 Mar;110(2):80-88. doi: 10.1016/j.ygeno.2017.08.009. Epub 2017 Sep 4.

PMID:
28882735
22.

Stromal and epithelial transcriptional map of initiation progression and metastatic potential of human prostate cancer.

Tyekucheva S, Bowden M, Bango C, Giunchi F, Huang Y, Zhou C, Bondi A, Lis R, Van Hemelrijck M, Andrén O, Andersson SO, Watson RW, Pennington S, Finn SP, Martin NE, Stampfer MJ, Parmigiani G, Penney KL, Fiorentino M, Mucci LA, Loda M.

Nat Commun. 2017 Sep 4;8(1):420. doi: 10.1038/s41467-017-00460-4.

23.

Role of stem-cell divisions in cancer risk.

Tomasetti C, Durrett R, Kimmel M, Lambert A, Parmigiani G, Zauber A, Vogelstein B.

Nature. 2017 Aug 9;548(7666):E13-E14. doi: 10.1038/nature23302. No abstract available.

PMID:
28796214
24.

Reassessing risk models for atypical hyperplasia: age may not matter.

Mazzola E, Coopey SB, Griffin M, Polubriaginof F, Buckley JM, Parmigiani G, Garber JE, Smith BL, Gadd MA, Specht MC, Guidi A, Hughes KS.

Breast Cancer Res Treat. 2017 Sep;165(2):285-291. doi: 10.1007/s10549-017-4320-7. Epub 2017 Jun 6. Review.

25.

Designing Clinical Trials That Accept New Arms: An Example in Metastatic Breast Cancer.

Ventz S, Alexander BM, Parmigiani G, Gelber RD, Trippa L.

J Clin Oncol. 2017 Sep 20;35(27):3160-3168. doi: 10.1200/JCO.2016.70.1169. Epub 2017 May 22.

PMID:
28530853
26.

[Mental capacity and capacity to consent: multicentric study in a involuntary psychiatric hospitalized patients sample].

Carabellese F, Mandarelli G, La Tegola D, Parmigiani G, Ferracuti S, Quartesan R, Bellomo A, Catanesi R.

Riv Psichiatr. 2017 Mar-Apr;52(2):67-74. doi: 10.1708/2679.27442. Italian.

PMID:
28492576
27.

MODELING DEPENDENT GENE EXPRESSION.

Telesca D, Müller P, Parmigiani G, Freedman RS.

Ann Stat. 2012;6(2):542-560. doi: 10.1214/11-AOAS525. Epub 2012 Jun 11.

28.

Propensity scores with misclassified treatment assignment: a likelihood-based adjustment.

Braun D, Gorfine M, Parmigiani G, Arvold ND, Dominici F, Zigler C.

Biostatistics. 2017 Oct 1;18(4):695-710. doi: 10.1093/biostatistics/kxx014.

29.

Leveraging molecular datasets for biomarker-based clinical trial design in glioblastoma.

Tanguturi SK, Trippa L, Ramkissoon SH, Pelton K, Knoff D, Sandak D, Lindeman NI, Ligon AH, Beroukhim R, Parmigiani G, Wen PY, Ligon KL, Alexander BM.

Neuro Oncol. 2017 Jul 1;19(7):908-917. doi: 10.1093/neuonc/now312.

30.

Free will, neuroscience, and choice: towards a decisional capacity model for insanity defense evaluations.

Parmigiani G, Mandarelli G, Meynen G, Tarsitani L, Biondi M, Ferracuti S.

Riv Psichiatr. 2017 Jan-Feb;52(1):9-15. doi: 10.1708/2631.27049. Review.

PMID:
28287192
31.

Treatment decision-making capacity in non-consensual psychiatric treatment: a multicentre study.

Mandarelli G, Carabellese F, Parmigiani G, Bernardini F, Pauselli L, Quartesan R, Catanesi R, Ferracuti S.

Epidemiol Psychiatr Sci. 2018 Oct;27(5):492-499. doi: 10.1017/S2045796017000063. Epub 2017 Mar 9.

PMID:
28274298
32.

Bayesian response-adaptive designs for basket trials.

Ventz S, Barry WT, Parmigiani G, Trippa L.

Biometrics. 2017 Sep;73(3):905-915. doi: 10.1111/biom.12668. Epub 2017 Feb 17.

PMID:
28211944
33.

Combinatorial Mixtures of Multiparameter Distributions: An Application to Bivariate Data.

Edefonti V, Parmigiani G.

Int J Biostat. 2017 Feb 16;13(1). pii: /j/ijb.2017.13.issue-1/ijb-2015-0064/ijb-2015-0064.xml. doi: 10.1515/ijb-2015-0064.

PMID:
28207413
34.

Adaptive Randomization of Neratinib in Early Breast Cancer.

Harrington D, Parmigiani G.

N Engl J Med. 2016 Oct 20;375(16):1593-4. doi: 10.1056/NEJMc1609993. No abstract available.

PMID:
28103002
35.

Model averaged double robust estimation.

Cefalu M, Dominici F, Arvold N, Parmigiani G.

Biometrics. 2017 Jun;73(2):410-421. doi: 10.1111/biom.12622. Epub 2016 Nov 28.

36.

I-SPY 2--A Glimpse of the Future of Phase 2 Drug Development?

Harrington D, Parmigiani G.

N Engl J Med. 2016 Jul 7;375(1):7-9. doi: 10.1056/NEJMp1602256. No abstract available.

PMID:
27406345
37.

Decisional Capacity to Consent to Clinical Research Involving Placebo in Psychiatric Patients.

Parmigiani G, Mandarelli G, Dacquino C, Pompili P, Lelli Chiesa G, Ferracuti S.

J Forensic Sci. 2016 Mar;61(2):388-393. doi: 10.1111/1556-4029.13000. Epub 2015 Dec 22.

PMID:
27404612
38.

The Doppelgänger Effect: Hidden Duplicates in Databases of Transcriptome Profiles.

Waldron L, Riester M, Ramos M, Parmigiani G, Birrer M.

J Natl Cancer Inst. 2016 Jul 5;108(11). doi: 10.1093/jnci/djw146. Print 2016 Nov.

39.

Penetrance of ATM Gene Mutations in Breast Cancer: A Meta-Analysis of Different Measures of Risk.

Marabelli M, Cheng SC, Parmigiani G.

Genet Epidemiol. 2016 Jul;40(5):425-31. doi: 10.1002/gepi.21971. Epub 2016 Apr 25.

PMID:
27112364
40.

A two-stage approach to genetic risk assessment in primary care.

Biswas S, Atienza P, Chipman J, Blackford AL, Arun B, Hughes K, Parmigiani G.

Breast Cancer Res Treat. 2016 Jan;155(2):375-83. doi: 10.1007/s10549-016-3686-2. Epub 2016 Jan 19.

41.

Familial Risk and Heritability of Cancer Among Twins in Nordic Countries.

Mucci LA, Hjelmborg JB, Harris JR, Czene K, Havelick DJ, Scheike T, Graff RE, Holst K, Möller S, Unger RH, McIntosh C, Nuttall E, Brandt I, Penney KL, Hartman M, Kraft P, Parmigiani G, Christensen K, Koskenvuo M, Holm NV, Heikkilä K, Pukkala E, Skytthe A, Adami HO, Kaprio J; Nordic Twin Study of Cancer (NorTwinCan) Collaboration.

JAMA. 2016 Jan 5;315(1):68-76. doi: 10.1001/jama.2015.17703. Erratum in: JAMA. 2016 Feb 23;315(8):822.

42.

Optimal Bayesian adaptive trials when treatment efficacy depends on biomarkers.

Zhang Y, Trippa L, Parmigiani G.

Biometrics. 2016 Jun;72(2):414-21. doi: 10.1111/biom.12437. Epub 2015 Nov 17.

PMID:
26575199
43.

Evaluating a 4-marker signature of aggressive prostate cancer using time-dependent AUC.

Gerke TA, Martin NE, Ding Z, Nuttall EJ, Stack EC, Giovannucci E, Lis RT, Stampfer MJ, Kantoff PW, Parmigiani G, Loda M, Mucci LA.

Prostate. 2015 Dec;75(16):1926-33. doi: 10.1002/pros.23090. Epub 2015 Sep 7.

44.

Recent Enhancements to the Genetic Risk Prediction Model BRCAPRO.

Mazzola E, Blackford A, Parmigiani G, Biswas S.

Cancer Inform. 2015 May 10;14(Suppl 2):147-57. doi: 10.4137/CIN.S17292. eCollection 2015. Review.

45.

Comparing Platforms for Messenger RNA Expression Profiling of Archival Formalin-Fixed, Paraffin-Embedded Tissues.

Tyekucheva S, Martin NE, Stack EC, Wei W, Vathipadiekal V, Waldron L, Fiorentino M, Lis RT, Stampfer MJ, Loda M, Parmigiani G, Mucci LA, Birrer M.

J Mol Diagn. 2015 Jul;17(4):374-81. doi: 10.1016/j.jmoldx.2015.02.002. Epub 2015 Apr 30.

46.

Accounting for uncertainty in confounder and effect modifier selection when estimating average causal effects in generalized linear models.

Wang C, Dominici F, Parmigiani G, Zigler CM.

Biometrics. 2015 Sep;71(3):654-65. doi: 10.1111/biom.12315. Epub 2015 Apr 20.

47.

BRCA1 recruitment to transcriptional pause sites is required for R-loop-driven DNA damage repair.

Hatchi E, Skourti-Stathaki K, Ventz S, Pinello L, Yen A, Kamieniarz-Gdula K, Dimitrov S, Pathania S, McKinney KM, Eaton ML, Kellis M, Hill SJ, Parmigiani G, Proudfoot NJ, Livingston DM.

Mol Cell. 2015 Feb 19;57(4):636-647. doi: 10.1016/j.molcel.2015.01.011.

48.

Combining progression-free survival and overall survival as a novel composite endpoint for glioblastoma trials.

Trippa L, Wen PY, Parmigiani G, Berry DA, Alexander BM.

Neuro Oncol. 2015 Aug;17(8):1106-13. doi: 10.1093/neuonc/nou345. Epub 2015 Jan 7.

49.

Only three driver gene mutations are required for the development of lung and colorectal cancers.

Tomasetti C, Marchionni L, Nowak MA, Parmigiani G, Vogelstein B.

Proc Natl Acad Sci U S A. 2015 Jan 6;112(1):118-23. doi: 10.1073/pnas.1421839112. Epub 2014 Dec 22.

50.

Differential and limited expression of mutant alleles in multiple myeloma.

Rashid NU, Sperling AS, Bolli N, Wedge DC, Van Loo P, Tai YT, Shammas MA, Fulciniti M, Samur MK, Richardson PG, Magrangeas F, Minvielle S, Futreal PA, Anderson KC, Avet-Loiseau H, Campbell PJ, Parmigiani G, Munshi NC.

Blood. 2014 Nov 13;124(20):3110-7. doi: 10.1182/blood-2014-04-569327. Epub 2014 Sep 18.

Supplemental Content

Loading ...
Support Center